Protalix BioTherapeutics 将于 2026 年 11 月 10 日公布 2026 年第三季度财务业绩及业务进展

Company to host conference call and webcast at 8:00 a.m. ET

, /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended September 30, 2026 and provide a business update on November 10, 2026.

Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments.

Conference Call Details:
Date:                           Tuesday, November 10, 2026
Time:                          8:00 a.m. Eastern Time (ET)
Toll Free:                   1-877-423-9813
International:             1-201-689-8573
Israeli Toll Free:        1-809-406-247
Conference ID:          13763420
Call me™:                  https://tinyurl.com/3awxvdvm
The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.

Webcast Details: 
The conference will be webcast live from the Protalix website and will be available via the following links:

Company Link:         https://ir.protalix.com/news-events/events
Webcast Link:           https://tinyurl.com/ye6k6b3n
Conference ID:          13763420

Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases. Protalix has researched, developed, and currently manufactures two enzyme replacement therapies that are currently available in multiple markets. These therapies are recombinant therapeutic proteins expressed through Protalix's proprietary plant cell-based expression system, ProCellEx^®. ProCellEx is a unique plant cell-based system that enables Protalix to produce recombinant proteins in an industrial-scale manner with no exposure to mammalian cells. Protalix is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa, Elelyso^®, for the treatment of Gaucher disease, excluding in Brazil where Protalix retains full rights.

Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio^® which was approved by both the FDA and the European Medicines Agency (EMA) in May 2023. Protalix's development pipeline includes, among others, two proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; and PRX–119, a plant cell-expressed long-acting DNase I for the treatment of NETs-related diseases. To learn more, please visit www.protalix.com.

Investor Contact
Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
[email protected]

SOURCE Protalix BioTherapeutics, Inc.